Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 112

1.

Phase I/II multisite trial of optimally dosed clofarabine and low-dose TBI for hematopoietic cell transplantation in acute myeloid leukemia.

Krakow EF, Gyurkocza B, Storer BE, Chauncey TR, McCune JS, Radich JP, Bouvier ME, Estey EH, Storb R, Maloney DG, Sandmaier BM.

Am J Hematol. 2019 Oct 22. doi: 10.1002/ajh.25665. [Epub ahead of print]

PMID:
31637757
2.

Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study.

Bekaii-Saab TS, Ou FS, Ahn DH, Boland PM, Ciombor KK, Heying EN, Dockter TJ, Jacobs NL, Pasche BC, Cleary JM, Meyers JP, Desnoyers RJ, McCune JS, Pedersen K, Barzi A, Chiorean EG, Sloan J, Lacouture ME, Lenz HJ, Grothey A.

Lancet Oncol. 2019 Aug;20(8):1070-1082. doi: 10.1016/S1470-2045(19)30272-4. Epub 2019 Jun 28.

PMID:
31262657
3.

Haploidentical hematopoietic cell and kidney transplantation for hematological malignancies and end-stage renal failure.

Chen YB, Elias N, Heher E, McCune JS, Collier K, Li S, Del Rio C, El-Jawahri A, Williams W, Tolkoff-Rubin N, Fishman JA, McAfee S, Dey BR, DeFilipp Z, O'Donnell PV, Cosimi AB, Sachs D, Kawai T, Spitzer TR.

Blood. 2019 Jul 11;134(2):211-215. doi: 10.1182/blood.2019000775. Epub 2019 May 31.

PMID:
31151984
4.

Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement.

McCune JS, Quinones CM, Ritchie J, Carpenter PA, van Maarseveen E, Yeh RF, Anasetti C, Boelens JJ, Hamerschlak N, Hassan M, Kang HJ, Kanda Y, Paci A, Perales MA, Shaw PJ, Seewaldt VL, Savani BN, Hsieh A, Poon B, Mohty M, Pulsipher MA, Pasquini M, Dupuis LL.

Biol Blood Marrow Transplant. 2019 Sep;25(9):1890-1897. doi: 10.1016/j.bbmt.2019.05.021. Epub 2019 May 25.

PMID:
31136799
5.

A marijuana-drug interaction primer: Precipitants, pharmacology, and pharmacokinetics.

Cox EJ, Maharao N, Patilea-Vrana G, Unadkat JD, Rettie AE, McCune JS, Paine MF.

Pharmacol Ther. 2019 Sep;201:25-38. doi: 10.1016/j.pharmthera.2019.05.001. Epub 2019 May 7. Review.

PMID:
31071346
6.

Association of Antiepileptic Medications with Outcomes after Allogeneic Hematopoietic Cell Transplantation with Busulfan/Cyclophosphamide Conditioning.

McCune JS, Wang T, Bo-Subait K, Aljurf M, Beitinjaneh A, Bubalo J, Cahn JY, Cerny J, Chhabra S, Cumpston A, Dupuis LL, Lazarus HM, Marks DI, Maziarz RT, Norkin M, Prestidge T, Mineishi S, Krem MM, Pasquini M, Martin PJ.

Biol Blood Marrow Transplant. 2019 Jul;25(7):1424-1431. doi: 10.1016/j.bbmt.2019.03.001. Epub 2019 Mar 11.

PMID:
30871976
7.

Developing User Personas to Aid in the Design of a User-Centered Natural Product-Drug Interaction Information Resource for Researchers.

Boyce RD, Ragueneau-Majlessi I, Yu J, Tay-Sontheimer J, Kinsella C, Chou E, Brochhausen M, Judkins J, Gufford BT, Pinkleton BE, Cooney R, Paine MF, McCune JS.

AMIA Annu Symp Proc. 2018 Dec 5;2018:279-287. eCollection 2018.

8.

Selection and characterization of botanical natural products for research studies: a NaPDI center recommended approach.

Kellogg JJ, Paine MF, McCune JS, Oberlies NH, Cech NB.

Nat Prod Rep. 2019 Aug 14;36(8):1196-1221. doi: 10.1039/c8np00065d. Review.

PMID:
30681109
9.

Correction: A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer.

Schweizer MT, Haugk K, McKiernan JS, Gulati R, Cheng HH, Maes JL, Dumpit RF, Nelson PS, Montgomery B, McCune JS, Plymate SR, Yu EY.

PLoS One. 2018 Aug 15;13(8):e0202709. doi: 10.1371/journal.pone.0202709. eCollection 2018.

10.

Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.

Hawkins DS, Chi YY, Anderson JR, Tian J, Arndt CAS, Bomgaars L, Donaldson SS, Hayes-Jordan A, Mascarenhas L, McCarville MB, McCune JS, McCowage G, Million L, Morris CD, Parham DM, Rodeberg DA, Rudzinski ER, Shnorhavorian M, Spunt SL, Skapek SX, Teot LA, Wolden S, Yock TI, Meyer WH.

J Clin Oncol. 2018 Sep 20;36(27):2770-2777. doi: 10.1200/JCO.2018.77.9694. Epub 2018 Aug 9.

11.

A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer.

Schweizer MT, Haugk K, McKiernan JS, Gulati R, Cheng HH, Maes JL, Dumpit RF, Nelson PS, Montgomery B, McCune JS, Plymate SR, Yu EY.

PLoS One. 2018 Jun 1;13(6):e0198389. doi: 10.1371/journal.pone.0198389. eCollection 2018. Erratum in: PLoS One. 2018 Aug 15;13(8):e0202709.

12.

Recommended Approaches for Pharmacokinetic Natural Product-Drug Interaction Research: a NaPDI Center Commentary.

Paine MF, Shen DD, McCune JS.

Drug Metab Dispos. 2018 Jul;46(7):1041-1045. doi: 10.1124/dmd.117.079962. Epub 2018 May 7.

13.

Selection of Priority Natural Products for Evaluation as Potential Precipitants of Natural Product-Drug Interactions: A NaPDI Center Recommended Approach.

Johnson EJ, González-Peréz V, Tian DD, Lin YS, Unadkat JD, Rettie AE, Shen DD, McCune JS, Paine MF.

Drug Metab Dispos. 2018 Jul;46(7):1046-1052. doi: 10.1124/dmd.118.081273. Epub 2018 May 7.

14.

Inosine Monophosphate Dehydrogenase Pharmacogenetics in Hematopoietic Cell Transplantation Patients.

McCune JS, Storer B, Thomas S, McKiernan J, Gupta R, Sandmaier BM.

Biol Blood Marrow Transplant. 2018 Sep;24(9):1802-1807. doi: 10.1016/j.bbmt.2018.04.006. Epub 2018 Apr 12.

15.

Rapid Advances in Immunotherapy to Treat Cancer.

McCune JS.

Clin Pharmacol Ther. 2018 Apr;103(4):540-544. doi: 10.1002/cpt.985.

PMID:
29527663
16.

Identification of Intestinal UDP-Glucuronosyltransferase Inhibitors in Green Tea (Camellia sinensis) Using a Biochemometric Approach: Application to Raloxifene as a Test Drug via In Vitro to In Vivo Extrapolation.

Tian DD, Kellogg JJ, Okut N, Oberlies NH, Cech NB, Shen DD, McCune JS, Paine MF.

Drug Metab Dispos. 2018 May;46(5):552-560. doi: 10.1124/dmd.117.079491. Epub 2018 Feb 21.

17.

Development and Validation of a Novel Acute Myeloid Leukemia-Composite Model to Estimate Risks of Mortality.

Sorror ML, Storer BE, Fathi AT, Gerds AT, Medeiros BC, Shami P, Brunner AM, Sekeres MA, Mukherjee S, Peña E, Elsawy M, Wardyn S, Whitten J, Moore R, Becker PS, McCune JS, Appelbaum FR, Estey EH.

JAMA Oncol. 2017 Dec 1;3(12):1675-1682. doi: 10.1001/jamaoncol.2017.2714.

18.

Prediction of Intravenous Busulfan Clearance by Endogenous Plasma Biomarkers Using Global Pharmacometabolomics.

Lin YS, Kerr SJ, Randolph T, Shireman LM, Senn T, McCune JS.

Metabolomics. 2016 Oct;12(10). pii: 161. doi: 10.1007/s11306-016-1106-6. Epub 2016 Sep 15.

19.

Hyperthermia-enhanced targeted drug delivery using magnetic resonance-guided focussed ultrasound: a pre-clinical study in a genetic model of pancreatic cancer.

Farr N, Wang YN, D'Andrea S, Starr F, Partanen A, Gravelle KM, McCune JS, Risler LJ, Whang SG, Chang A, Hingorani SR, Lee D, Hwang JH.

Int J Hyperthermia. 2018 May;34(3):284-291. doi: 10.1080/02656736.2017.1336675. Epub 2017 Jul 17.

20.
21.

Comparison of Metabolomics Approaches for Evaluating the Variability of Complex Botanical Preparations: Green Tea (Camellia sinensis) as a Case Study.

Kellogg JJ, Graf TN, Paine MF, McCune JS, Kvalheim OM, Oberlies NH, Cech NB.

J Nat Prod. 2017 May 26;80(5):1457-1466. doi: 10.1021/acs.jnatprod.6b01156. Epub 2017 Apr 28.

22.

Why has model-informed precision dosing not yet become common clinical reality? lessons from the past and a roadmap for the future.

Darwich AS, Ogungbenro K, Vinks AA, Powell JR, Reny JL, Marsousi N, Daali Y, Fairman D, Cook J, Lesko LJ, McCune JS, Knibbe C, de Wildt SN, Leeder JS, Neely M, Zuppa AF, Vicini P, Aarons L, Johnson TN, Boiani J, Rostami-Hodjegan A.

Clin Pharmacol Ther. 2017 May;101(5):646-656. doi: 10.1002/cpt.659. Epub 2017 Apr 4. Review.

PMID:
28182269
23.

Mortality outcomes after busulfan-containing conditioning treatment and haemopoietic cell transplantation in patients with Gilbert's syndrome: a retrospective cohort study.

McDonald GB, Evans AT, McCune JS, Schoch G, Ostrow JD, Gooley TA.

Lancet Haematol. 2016 Nov;3(11):e516-e525. doi: 10.1016/S2352-3026(16)30149-1.

PMID:
27968820
24.

Immunotherapy to Treat Cancer.

McCune JS.

Clin Pharmacol Ther. 2016 Sep;100(3):198-203. doi: 10.1002/cpt.404.

PMID:
27513619
25.

Personalizing Busulfan-Based Conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee.

Palmer J, McCune JS, Perales MA, Marks D, Bubalo J, Mohty M, Wingard JR, Paci A, Hassan M, Bredeson C, Pidala J, Shah N, Shaughnessy P, Majhail N, Schriber J, Savani BN, Carpenter PA.

Biol Blood Marrow Transplant. 2016 Nov;22(11):1915-1925. doi: 10.1016/j.bbmt.2016.07.013. Epub 2016 Jul 29. Review.

26.

Pharmacometabonomic Prediction of Busulfan Clearance in Hematopoetic Cell Transplant Recipients.

Navarro SL, Randolph TW, Shireman LM, Raftery D, McCune JS.

J Proteome Res. 2016 Aug 5;15(8):2802-11. doi: 10.1021/acs.jproteome.6b00370. Epub 2016 Jul 20.

27.

Comorbidities, Alcohol Use Disorder, and Age Predict Outcomes after Autologous Hematopoietic Cell Transplantation for Lymphoma.

Graf SA, Vaughn JE, Chauncey TR, Storer BE, Gopal AK, Holmberg LA, McCune JS, Bensinger WI, Maloney DG, Press OW, Storb R, Sorror ML.

Biol Blood Marrow Transplant. 2016 Sep;22(9):1582-1587. doi: 10.1016/j.bbmt.2016.06.007. Epub 2016 Jun 14.

28.

Levetiracetam for the prevention of busulfan-induced seizures in pediatric hematopoietic cell transplantation recipients.

Floeter AE, McCune JS.

J Oncol Pharm Pract. 2017 Jul;23(5):344-349. doi: 10.1177/1078155216651128. Epub 2016 May 20.

PMID:
27208016
29.

The Clinical and Economic Impacts of Skeletal-Related Events Among Medicare Enrollees With Prostate Cancer Metastatic to Bone.

McDougall JA, Bansal A, Goulart BH, McCune JS, Karnopp A, Fedorenko C, Greenlee S, Valderrama A, Sullivan SD, Ramsey SD.

Oncologist. 2016 Mar;21(3):320-6. doi: 10.1634/theoncologist.2015-0327. Epub 2016 Feb 10.

30.

Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation.

Mielcarek M, Furlong T, O'Donnell PV, Storer BE, McCune JS, Storb R, Carpenter PA, Flowers ME, Appelbaum FR, Martin PJ.

Blood. 2016 Mar 17;127(11):1502-8. doi: 10.1182/blood-2015-10-672071. Epub 2016 Jan 13.

31.

Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Immunosuppressants in Allogeneic Hematopoietic Cell Transplantation: Part II.

McCune JS, Bemer MJ, Long-Boyle J.

Clin Pharmacokinet. 2016 May;55(5):551-93. doi: 10.1007/s40262-015-0340-9. Review.

32.

Pharmacokinetics, Pharmacodynamics and Pharmacogenomics of Immunosuppressants in Allogeneic Haematopoietic Cell Transplantation: Part I.

McCune JS, Bemer MJ.

Clin Pharmacokinet. 2016 May;55(5):525-50. doi: 10.1007/s40262-015-0339-2. Review.

33.

Pulsed High-Intensity Focused Ultrasound Enhances Delivery of Doxorubicin in a Preclinical Model of Pancreatic Cancer.

Li T, Wang YN, Khokhlova TD, D'Andrea S, Starr F, Chen H, McCune JS, Risler LJ, Mashadi-Hossein A, Hingorani SR, Chang A, Hwang JH.

Cancer Res. 2015 Sep 15;75(18):3738-46. doi: 10.1158/0008-5472.CAN-15-0296. Epub 2015 Jul 27. Erratum in: Cancer Res. 2017 May 15;77(10 ):2771.

34.

Developing and Using Therapeutics for Emerging Infections.

McCune JS, Reynolds KS.

Clin Pharmacol Ther. 2015 Oct;98(4):346-51. doi: 10.1002/cpt.183.

PMID:
26179402
35.

Association of fludarabine pharmacokinetic/dynamic biomarkers with donor chimerism in nonmyeloablative HCT recipients.

McCune JS, Mager DE, Bemer MJ, Sandmaier BM, Storer BE, Heimfeld S.

Cancer Chemother Pharmacol. 2015 Jul;76(1):85-96. doi: 10.1007/s00280-015-2768-x. Epub 2015 May 17.

36.

Making pharmacogenomic-based prescribing alerts more effective: A scenario-based pilot study with physicians.

Overby CL, Devine EB, Abernethy N, McCune JS, Tarczy-Hornoch P.

J Biomed Inform. 2015 Jun;55:249-59. doi: 10.1016/j.jbi.2015.04.011. Epub 2015 May 7.

37.

Population pharmacokinetic/dynamic model of lymphosuppression after fludarabine administration.

McCune JS, Vicini P, Salinger DH, O'Donnell PV, Sandmaier BM, Anasetti C, Mager DE.

Cancer Chemother Pharmacol. 2015 Jan;75(1):67-75. doi: 10.1007/s00280-014-2618-2. Epub 2014 Nov 6.

38.

Optimizing drug therapy in pediatric SCT: focus on pharmacokinetics.

McCune JS, Jacobson P, Wiseman A, Militano O.

Bone Marrow Transplant. 2015 Feb;50(2):165-72. doi: 10.1038/bmt.2014.235. Epub 2014 Oct 27. Review.

39.

Predictive performance of a physiologically based pharmacokinetic model of busulfan in children.

Diestelhorst C, Boos J, McCune JS, Russell J, Kangarloo SB, Hempel G.

Pediatr Hematol Oncol. 2014 Nov;31(8):731-42. doi: 10.3109/08880018.2014.927945. Epub 2014 Jul 9.

PMID:
25007236
40.

Recipient pretransplant inosine monophosphate dehydrogenase activity in nonmyeloablative hematopoietic cell transplantation.

Bemer MJ, Risler LJ, Phillips BR, Wang J, Storer BE, Sandmaier BM, Duan H, Raccor BS, Boeckh MJ, McCune JS.

Biol Blood Marrow Transplant. 2014 Oct;20(10):1544-52. doi: 10.1016/j.bbmt.2014.05.032. Epub 2014 Jun 9.

41.

Population pharmacokinetics of intravenous busulfan in children: revised body weight-dependent NONMEM® model to optimize dosing.

Diestelhorst C, Boos J, McCune JS, Hempel G.

Eur J Clin Pharmacol. 2014 Jul;70(7):839-47. doi: 10.1007/s00228-014-1692-z. Epub 2014 May 9.

PMID:
24810613
42.

Pharmacokinetic and pharmacodynamic analysis of inosine monophosphate dehydrogenase activity in hematopoietic cell transplantation recipients treated with mycophenolate mofetil.

Li H, Mager DE, Sandmaier BM, Storer BE, Boeckh MJ, Bemer MJ, Phillips BR, Risler LJ, McCune JS.

Biol Blood Marrow Transplant. 2014 Aug;20(8):1121-9. doi: 10.1016/j.bbmt.2014.03.032. Epub 2014 Apr 13.

43.

Busulfan in infant to adult hematopoietic cell transplant recipients: a population pharmacokinetic model for initial and Bayesian dose personalization.

McCune JS, Bemer MJ, Barrett JS, Scott Baker K, Gamis AS, Holford NH.

Clin Cancer Res. 2014 Feb 1;20(3):754-63. doi: 10.1158/1078-0432.CCR-13-1960. Epub 2013 Nov 11.

44.

Physiologically based pharmacokinetic modelling of Busulfan: a new approach to describe and predict the pharmacokinetics in adults.

Diestelhorst C, Boos J, McCune JS, Russell J, Kangarloo SB, Hempel G.

Cancer Chemother Pharmacol. 2013 Nov;72(5):991-1000. doi: 10.1007/s00280-013-2275-x. Epub 2013 Sep 6.

PMID:
24061863
45.

A pilot pharmacologic biomarker study in HLA-haploidentical hematopoietic cell transplant recipients.

Bemer MJ, Sorror M, Sandmaier BM, O'Donnell PV, McCune JS.

Cancer Chemother Pharmacol. 2013 Sep;72(3):607-18. doi: 10.1007/s00280-013-2232-8. Epub 2013 Aug 2.

46.

High prevalence of potential drug interactions affecting mycophenolic acid pharmacokinetics in nonmyeloablative hematopoietic stem cell transplant recipients.

Jaklič A, Collins CJ, Mrhar A, Sorror ML, Sandmaier BM, Bemer MJ, Locatelli I, McCune JS.

Int J Clin Pharmacol Ther. 2013 Sep;51(9):711-7. doi: 10.5414/CP201884.

47.

Nonrelapse mortality and mycophenolic acid exposure in nonmyeloablative hematopoietic cell transplantation.

McDermott CL, Sandmaier BM, Storer B, Li H, Mager DE, Boeckh MJ, Bemer MJ, Knutson J, McCune JS.

Biol Blood Marrow Transplant. 2013 Aug;19(8):1159-66. doi: 10.1016/j.bbmt.2013.04.026. Epub 2013 May 6.

48.

Cyclophosphamide followed by intravenous targeted busulfan for allogeneic hematopoietic cell transplantation: pharmacokinetics and clinical outcomes.

Rezvani AR, McCune JS, Storer BE, Batchelder A, Kida A, Deeg HJ, McDonald GB.

Biol Blood Marrow Transplant. 2013 Jul;19(7):1033-9. doi: 10.1016/j.bbmt.2013.04.005. Epub 2013 Apr 10.

49.

Variation in prescribing patterns and therapeutic drug monitoring of intravenous busulfan in pediatric hematopoietic cell transplant recipients.

McCune JS, Baker KS, Blough DK, Gamis A, Bemer MJ, Kelton-Rehkopf MC, Winter L, Barrett JS.

J Clin Pharmacol. 2013 Mar;53(3):264-75. doi: 10.1177/0091270012447196. Epub 2013 Jan 24.

50.

Population pharmacokinetics and dose optimization of mycophenolic acid in HCT recipients receiving oral mycophenolate mofetil.

Li H, Mager DE, Sandmaier BM, Maloney DG, Bemer MJ, McCune JS.

J Clin Pharmacol. 2013 Apr;53(4):393-402. doi: 10.1002/jcph.14. Epub 2013 Feb 4.

Supplemental Content

Loading ...
Support Center